The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci

被引:30
作者
Harris, Shannon L. [1 ]
Tan, Cuiwen [1 ]
Andrew, Lubomira [1 ]
Hao, Li [1 ]
Liberator, Paul A. [1 ]
Absalon, Judith [2 ]
Anderson, Annaliesa S. [1 ]
Jones, Thomas R. [1 ]
机构
[1] Pfizer Vaccine Res & Dev, Pearl River, NY USA
[2] Pfizer Vaccine Clin Res & Dev, Pearl River, NY USA
关键词
Neisseria meningitidis; MenB-FHbp; Serum bactericidal assay; Meningococcal disease; factor H binding protein; Vaccination; NEISSERIA-MENINGITIDIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DISEASE RECOMMENDATIONS; INVASIVE DISEASE; SERUM; STRAINS; ADOLESCENTS; CANDIDATE; OUTBREAKS;
D O I
10.1016/j.vaccine.2018.05.081
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
MenB-FHbp (Trumenba (R) ; bivalent rLP2086) is a meningococcal serogroup B vaccine containing 2 variants of the recombinant lipidated factor H binding protein (FHbp) antigen. The expression of FHbp, an outer membrane protein, is not restricted to serogroup B strains of Neisseria meningitidis (MenB). This study investigated whether antibodies elicited by MenB-FHbp vaccination also protect against non-MenB strains. Immunological responses were assessed in serum bactericidal assays using human complement (hSBAs) with non-MenB disease-causing test strains from Europe, Africa, and the United States. Importantly, FHbp variant distribution varies among meningococcal serogroups; therefore, strains that code for serogroup-specific prevalent variants (ie, representative of the 2 antigenically distinct FHbp subfamilies, designated subfamily A and subfamily B) and with moderate levels of FHbp surface expression were selected for testing by hSBA. After 2 or 3 doses of MenB-FHbp, 53% to 100% of individuals had bactericidal responses (hSBA titers >= 1:8) against meningococcal serogroup C, W, Y, and X strains, and 20% to 28% had bactericidal responses against serogroup A strains; in fact, these bactericidal responses elicited by MenB-FHbp antibodies against non-MenB strains, including strains associated with emerging disease, were greater than the serological correlate of protection for meningococcal disease (ie, hSBA titers >= 1:4). This is in comparison to a quadrivalent polysaccharide conjugate vaccine, MCV4 (Menactra (R), targeting meningococcal serogroups A, C, W, and Y), which elicited bactericidal responses of 90% to 97% against the serogroup A, C, W, and Y strains and had no activity against serogroup X. Together, these results provide clinical evidence that MenB-FHbp may protect against meningococcal disease regardless of serogroup. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6867 / 6874
页数:8
相关论文
共 52 条
  • [41] A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013
    O'Connor, L.
    Ward, M.
    Bennett, D.
    Mulhall, R.
    O'Lorcain, P.
    Cunney, R.
    McDermott, R.
    Neville, E.
    Heslin, J.
    FitzGerald, R.
    Meyler, K.
    Conlon, M.
    Clarke, A.
    Corcoran, B.
    Fitzpatrick, G.
    O'Connor, B.
    Flanagan, P.
    O'Flanagan, D.
    Cotter, S.
    [J]. EUROSURVEILLANCE, 2015, 20 (21)
  • [42] Case-Control Study of Risk Factors for Meningococcal Disease in Chile
    Olea, Andrea
    Matute, Isabel
    Gonzalez, Claudia
    Delgado, Iris
    Poffald, Lucy
    Pedroni, Elena
    Alfaro, Tania
    Hirmas, Macarena
    Najera, Manuel
    Gormaz, Ana
    Lopez, Dario
    Loayza, Sergio
    Ferreccio, Catterina
    Gallegos, Doris
    Fuentes, Rodrigo
    Vial, Pablo
    Aguilera, Ximena
    [J]. EMERGING INFECTIOUS DISEASES, 2017, 23 (07) : 1070 - 1078
  • [43] Ostergaard L, 2016, PHASE 3 TRIAL IMMUNO
  • [44] Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37
    Seib, K. L.
    Serruto, D.
    Oriente, F.
    Delany, I.
    Adu-Bobie, J.
    Veggi, D.
    Arico, B.
    Rappuoli, R.
    Pizza, M.
    [J]. INFECTION AND IMMUNITY, 2009, 77 (01) : 292 - 299
  • [45] Meningococci of Serogroup X Clonal Complex 181 in Refugee Camps, Italy
    Stefanelli, Paola
    Neri, Arianna
    Vacca, Paola
    Picicco, Damiano
    Daprai, Laura
    Mainardi, Giulia
    Rossolini, Gian Maria
    Bartoloni, Alessandro
    Anselmo, Anna
    Ciammaruconi, Andrea
    Fortunato, Antonella
    Palozzi, Anna Maria
    Fillo, Silvia
    Faccini, Marino
    Senatore, Sabrina
    Lista, Florigio
    Fazio, Cecilia
    [J]. EMERGING INFECTIOUS DISEASES, 2017, 23 (05) : 870 - 872
  • [46] Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
    Stephens, David S.
    Greenwood, Brian
    Brandtzaeg, Petter
    [J]. LANCET, 2007, 369 (9580) : 2196 - 2210
  • [47] Serogroup W135 meningococcal disease in Hajj pilgrims
    Taha, MK
    Achtman, M
    Alonso, JM
    Greenwood, B
    Ramsay, M
    Fox, A
    Gray, S
    Kaczmarski, E
    [J]. LANCET, 2000, 356 (9248) : 2159 - 2159
  • [48] Conventional and molecular investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, Greece
    Tzanakaki, G.
    Kesanopoulos, K.
    Yazdankhah, S. P.
    Levidiotou, S.
    Kremastinou, J.
    Caugant, D. A.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (10) : 1024 - 1026
  • [49] Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study
    Viner, Russell M.
    Booy, Robert
    Johnson, Helen
    Edmunds, W. John
    Hudson, Lee
    Bedford, Helen
    Kaczmarski, Ed
    Rajput, Kaukab
    Ramsay, Mary
    Christie, Deborah
    [J]. LANCET NEUROLOGY, 2012, 11 (09) : 774 - 783
  • [50] History of meningococcal vaccines and their serological correlates of protection
    Vipond, Caroline
    Care, Rory
    Feavers, Ian M.
    [J]. VACCINE, 2012, 30 : B10 - B17